EUVIMEDEUVIMED entdecken
Crossref

An epidermal growth factor receptor‐targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer

Mei Huang iD, Jisoo Park iD, Jina Seo iD, Sanghwan Ko iD, Yoon Hee Yang iD, Yeaji Lee iD, Hyo Jeong Kim iD, Bok-Soon Lee iD, Yun Sang Lee iD, Byoung Joon Ko iD, Sang Teak Jung iD, Deachan Park iD und 2 weitere

The FASEB Journal · 2024

DOI: 10.1096/fj.202301968r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Mei Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Graduate School of Ajou University, Suwon, Republic of Korea. Hauptthemen laut MEDLINE: ErbB Receptors, Immunotoxins, Head and Neck Neoplasms, Immunoglobulin G. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Korea Health Industry Development Institute (KHIDI), National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The epidermal growth factor receptor (EGFR) is an important target for cancer therapies. Many head and neck cancer (HNC) cells have been reported to overexpress EGFR; therefore, anti‐EGFR therapies have been attempted in patients with HNC. However, its clinical efficacy is limited owing to the development of drug resistance. In this study, we developed an EGFR‐targeting immunotoxin consisting of a clinically proven anti‐EGFR IgG (cetuximab; CTX) and a toxin fragment (LR‐LO10) derived from Pseudomonas exotoxin A (PE) using a novel site‐specific conjugation technology (peptide‐directed photo‐crosslinking reaction), as an alternative option. The immunotoxin (CTX‐LR‐LO10) showed specific binding to EGFR and properties of a typical IgG, such as stability, interactions with receptors of immune cells, and pharmacokinetics, and inhibited protein synthesis via modification of elongation factor‐2. Treatment of EGFR‐positive HNC cells with the immunotoxin resulted in apoptotic cell death and the inhibition of cell migration and invasion. The efficacy of CTX‐LR‐LO10 was evaluated in xenograft mouse models, and the immunotoxin exhibited much stronger tumor suppression than CTX or LR‐LO10. Transcriptome analyses revealed that the immunotoxins elicited immune responses and altered the expression of genes related to its mechanisms of action. These results support the notion that CTX‐LR‐LO10 may serve as a new therapeutic agent targeting EGFR‐positive cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsImmunotoxinsHead and Neck NeoplasmsImmunoglobulin GVirulence FactorsPseudomonas aeruginosa Exotoxin AExotoxinsADP Ribose TransferasesHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysCetuximabMice, NudeBacterial ToxinsApoptosisMice, Inbred BALB CFemaleCell MovementAntineoplastic Agents

Stichwörter der Autor:innen

antibody‐drug conjugatecetuximabepidermal growth factor receptorhead and neck cancerimmunotoxinpeptide‐directed photo‐crosslinking

Substanzen

ErbB ReceptorsImmunotoxinsEGFR protein, humanImmunoglobulin GVirulence FactorsPseudomonas aeruginosa Exotoxin AExotoxinsADP Ribose TransferasesCetuximabBacterial Toxins

Autor:innen und Institutionen

  • Department of Medical Sciences, Graduate School of Ajou University, Suwon, Republic of Korea.
  • Department of Molecular Science and Technology, Ajou University, Suwon, Republic of Korea.
  • Department of Biomedical Sciences, Graduate School, Korea University, Seoul, Republic of Korea.
  • Department of Biomedical Sciences, Graduate School of Ajou University, Suwon, Republic of Korea.
  • Department of Otolaryngology, Ajou University School of Medicine, Suwon, Republic of Korea.
  • School of Biopharmaceutical and Medical Sciences, Sungshin Women's University, Seoul, Republic of Korea.

ORCID-Profile: Mei Huang, Jisoo Park, Jina Seo, Sanghwan Ko, Yoon Hee Yang, Yeaji Lee, Hyo Jeong Kim, Bok-Soon Lee, Yun Sang Lee, Byoung Joon Ko, Sang Teak Jung, Deachan Park, Tae Hyeon Yoo, Chul-Ho Kim

Förderung

  • Korea Health Industry Development Institute (KHIDI)
  • National Research Foundation of Korea (NRF)

Zitieren

APA

Huang, M., Park, J., Seo, J., Ko, S., Yang, Y. H., Lee, Y., Kim, H. J., Lee, B. S., Lee, Y. S., Ko, B. J., Jung, S. T., Park, D., Yoo, T. H., & Kim, C. H. (2024). An epidermal growth factor receptor‐targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer. The FASEB Journal. https://doi.org/10.1096/fj.202301968r

Vancouver

Huang M, Park J, Seo J, Ko S, Yang YH, Lee Y, et al. An epidermal growth factor receptor‐targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer. The FASEB Journal. 2024. doi:10.1096/fj.202301968r

BibTeX
@article{Huang2024,
  author = {Huang, Mei and Park, Jisoo and Seo, Jina and Ko, Sanghwan and Yang, Yoon Hee and Lee, Yeaji and Kim, Hyo Jeong and Lee, Bok-Soon and Lee, Yun Sang and Ko, Byoung Joon and Jung, Sang Teak and Park, Deachan and Yoo, Tae Hyeon and Kim, Chul-Ho},
  title = {An epidermal growth factor receptor‐targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer},
  journal = {The FASEB Journal},
  year = {2024},
  doi = {10.1096/fj.202301968r}
}
Kostenlos starten →